Journal Article Review Epublish
PubMed: 39897698 DOI: 10.1016/j.crmicr.2025.100341
The evolution of antifungal therapy: Traditional agents, current challenges and future perspectives.
Curr Res Microb Sci 8:100341
Authors: Cássia Milena de Souza, Bárbara Tavares Bezerra, Daniel Agreda Mellon, Haroldo Cesar de Oliveira
Affiliations
- Instituto Carlos Chagas, Fundação Oswaldo Cruz (Fiocruz), Curitiba, PR, Brazil.
- Instituto Carlos Chagas, Fundação Oswaldo Cruz (Fiocruz), Curitiba, PR, Brazil. Programa de Pós-Graduação em Biologia Parasitária, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil.
- Department of Microbiology, Immunology, and Parasitology, Discipline of Cellular Biology, Federal University of São Paulo (UNIFESP), São Paulo, Brazil.
Abstract
Fungal infections kill more than 3 million people every year. This high number reflects the significant challenges that treating these diseases worldwide presents. The current arsenal of antifungal drugs is limited and often accompanied by high toxicity to patients, elevated treatment costs, increased frequency of resistance rates, and the emergence of naturally resistant species. These treatment challenges highlight the urgency of developing new antifungal therapies, which could positively impact millions of lives each year globally. Our review offers an overview of the antifungal drugs currently available for treatment, presents the status of new antifungal drugs under clinical study, and explores ahead to future candidates that aim to help address this important global health issue.
MeSH
Pharmaceutical Preparations, Therapeutics